Tasbeeh Ahmed: Exploring Anticoagulation in Antiphospholipid Syndrome
Tasbeeh Ahmed, Medical Doctor, shared a post on LinkedIn:
“A clot may be the event. APS may be the reason.
Despite the widespread adoption of DOACs, Antiphospholipid Syndrome (APS) remains one of the most important exceptions in modern anticoagulation.
For many patients with thrombotic APS, the choice of anticoagulant is not just a prescription – it can determine the risk of recurrent DVT, stroke, limb ischemia, or pregnancy complications.
- When is Warfarin still the gold standard?
- Why are DOACs discouraged in triple-positive APS?
- What should we do when thrombosis recurs despite therapeutic INR?
- How does management change during pregnancy?
I created this infographic to provide a concise, evidence-based overview of the latest APS anticoagulation recommendations and help clinicians navigate these critical decisions with confidence.
Because in APS, choosing the right anticoagulant can be the difference between preventing the next thrombosis – or missing the opportunity.
What has been your experience managing APS patients in clinical practice?”
-
Jun 25, 2026, 14:13Christelle Orlando: 3 open Co-Chair Positions within the ISTH SSC Subcommittee on PAT
-
Jun 25, 2026, 14:10Brian A Beh: The Ten Truths That Changed How I Understand Stroke Recovery
-
Jun 25, 2026, 14:05Ryan O’Keefe: Exploring Gaucher’s Disease
-
Jun 25, 2026, 13:58Maha Othman: Guest Editing a Landmark STH Special Issue on the Role of Red Blood Cells in Hemostasis and Thrombosis
-
Jun 25, 2026, 13:45Judith Verlaan: Body Fat Distribution and Its Role in Coagulation and VTE Risk
-
Jun 25, 2026, 13:38Sonal Sonu: Kell VS Rh – Not All Blood Group Systems Affect Erythropoiesis the Same Way
-
Jun 25, 2026, 13:35Mariann Bautista: Simplifying Coagulation Quality Control
-
Jun 25, 2026, 13:31Stéphane Laurent: Key Highlights of ISBT 2026 for INLOG
-
Jun 25, 2026, 13:29Melinda Barkhuizen: When Neurology Meets Hematology – Parkinson’s Disease Genes in Platelets